Predix Pharmaceuticals Fax:1-781-376-0822

Jul 10 2003 13:06

P. 02

Appl. No.: 09/484,331 Amdt. Dated: July 10, 2003 Reply to Office Action of: January 13, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Application of

Harrington J. et al.

Art Unit: 1632

Application No.: 09/484,331

Examiner: R. Shukla

Filed: January 18, 2000

Atty. Docket: 0221-0003L

For:

Compositions and Methods For Non-Targeted Activation

of Endogenous Genes

DECLARATION UNDER 37 C.F.R. § 1.132

Assistant Commissioner of Patents and Trademark Washington, D.C. 20231

Sir:

The undersigned, Dale S. Dhanoa, Ph.D., declares and states:

I am currently Senior Vice President of Research and Discovery at Predix Pharmaconticals, Inc. in Woburn, Massachusetts. I submit that I specialize in the fields of drug discovery, design, synthesis, biological and pharmacological characterization of molecules (both non-peptide and peptide) for drug development, high throughput screening, binding assays, functional assays, cell-based assays, medicinal chemistry, combinatorial chemistry, and computational chemistry, as evidenced by my attached resume and the publication list. See, in particular, the short list of references 1-20 attached to this Declaration. Based on my knowledge and experience, I believe I am

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Application of

Harrington J. et al. Art Unit: 1632

Application No.: 09/484,331 Examiner: R. Shukla

Filed: January 18, 2000 Atty. Docket: 0221-0003L

For: Compositions and Methods
For Non-Targeted Activation
of Endogenous Genes

DECLARATION UNDER C.F.R. § 1.132

Assistant Commissioner of Patents and Trademark Washington, D.C. 20231

Sir:

The undersigned, Youssef L. Bennani, declares and states:

I am Director of Medicinal Chemistry at Athersys, Inc., the subject of the attached Curriculum Vitae and author of the publications shown on the list attached thereto. I was trained as an organic chemist from 1980-1991 (PhD) and have practiced in the field of medicinal chemistry and drug discovery for the past 12 years. I have been part of and led several drug discovery programs in various therapeutic areas at some of the top biopharmaceutical and pharmaceutical companies in the world, including Ligand Pharmaceuticals and Abbott Laboratories. To date, I have been associated with and responsible for discovering 5 or more drugs, one of which is a marketed drug, while others are in various pre-clinical and clinical stages of development. On the basis of

Considered 9W 21,3/05